FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

20040	D.O.	vvasiniigtori,

OMB APPR	OVAL				
OMB Number:	3235-0287				
Estimated average bur	den				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Nussbaum Rodney L					2. Issuer Name and Ticker or Trading Symbol GYRE THERAPEUTICS, INC. [GYRE]							(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(Fi	rst) ((Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/20/2024								Office below	r (give title)		Other (s below)	pecify
C/O GYRE THERAPEUTICS, INC. 12770 HIGH BLUFF DRIVE, SUITE 150				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) SAN DIEGO CA 92130													Form filed by More than One Reporting Person					
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Deriva						Sec	uritie	s Ac	quired, D	isp	osed o	f, or Be	neficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Code (Ins	Transaction Disposed Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4		Benefic Owned	es I ially (Following (Form (D) o	r Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	′	Amount	(A) or (D) Price		Reporte Transac (Instr. 3	ction(s)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,		ransaction Code (Instr.		tive ties ed sed	6. Date Exerc Expiration D (Month/Day/	ate		and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Co					Code	v	(A)	(D)	Date Exercisable	Ex	piration te	Title	Amount or Number of Shares	nber				
Stock Option (Right to Buy)	\$17.86	03/20/2024			Α		1,866		(1)	03/	/20/2034	Common Stock	1,866	\$0	1,866		D	

Explanation of Responses:

1. These options vest as to one-third on each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

/s/ Ruoyu Chen, as attorney-in-03/21/2024 fact for Rodney Nussbaum

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.